The DOI matches its Crossref record; 139 of the 140 references it cites were found in a registry or an index.
Benefits and Risks of Pharmacological Treatments for Essential Tremor
Abstract
Essential tremor can cause significant functional disability in some patients. The arms are the most common body part affected and cause the most functional disability. The treatment of essential tremor includes medications, surgical options and other forms of therapy. Presently there is no cure for essential tremor nor are there any medications that can slow the progression of tremor. Treatment for essential tremor is recommended if the tremor causes functional disability. If the tremor is disabling only during periods of stress and anxiety, propranolol and benzodiazepines can be used during those periods when the tremor causes functional disability. The currently available medications can improve tremor in approximately 50% of the patients. If the tremor is disabling, treatment should be initiated with either primidone or propranolol. If either primidone or propranolol do not provide adequate control of the tremor, then the medications can be used in combination. If patients experience adverse effects with propranolol, occasionally other beta-adrenoceptor antagonists (such as atenolol or metoprolol) can be used. If primidone and propranolol do not provide adequate control of tremor, occasionally the use of benzodiazepines (such as clonazepam) can provide benefit. Other medications that may be helpful include gabapentin or topiramate. If a patient has disabling head or voice tremor, botulinum toxin injections into the muscles may provide relief from the tremor. Botulinum toxin in the hand muscles for hand tremor can result in bothersome hand weakness and is not widely used. There are other medications that have been tried in essential tremor and have questionable efficacy. These drugs include carbonic anhydrase inhibitors (e.g. methazolamide), phenobarbital, calcium channel antagonists (e.g. nimodipine), isoniazid, clonidine, clozapine and mirtazapine. If the patient still has disabling tremor after medication trials, surgical options are usually considered. Surgical options include thalamotomy and deep brain stimulation of the thalamus. These surgical options provide adequate tremor control in approximately 90% of the patients. Surgical morbidity and mortality for these procedures is low. Deep brain stimulation and thalamotomy have been shown to have comparable efficacy but fewer complications have been reported with deep brain stimulation. In patients undergoing bilateral procedures deep brain stimulation of the thalamus is the procedure of choice to avoid adverse effects seen with bilateral ablative procedures. The use of medication and/or surgery can provide adequate tremor control in the majority of the patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Individuals with a disabling or medication refractory tremor, may have the option for one of several surgical procedures in the form of Deep Brain Stimulation (DBS), lesioning techniques such as γ knife radiosurgery (invasive), and magnetic resonance-guided focused ultrasound (non-invasive) [9, 10].”
From Controlling a motorized orthosis to follow elbow volitional movement: tests with individuals with pathological tremor (2019) · cites this paper as [9]
In the citing paper
“When medications are effective, the expected tremor reduction is around 50–60% [6, 9].”
From Controlling a motorized orthosis to follow elbow volitional movement: tests with individuals with pathological tremor (2019) · cites this paper as [9]
Citations
Cites
Gamma- Knife Radiosurgery for Pituitary Adenomas
Heinrich, Z. (2005) · Cited by 2,355
Consensus Statement of the Movement Disorder Society on Tremor
Deuschl, G., Bain, P., & Brin, M. (2008) · Movement Disorders · doi:10.1002/mds.870131303 · Cited by 1,981
Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus
Benabid, A. L., Pollak, P., Hoffmann, D., Gervason, C., Hommel, M., Perret, J. E., de Rougemont, J., & Gao, D. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)91175-t · Cited by 1,787
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
Benabid, A. L., Pollak, P., Gao, D., Hoffmann, D., Limousin, P., Gay, E., Payen, I., & Benazzouz, A. (1996) · Journal of Neurosurgery · doi:10.3171/jns.1996.84.2.0203 · Cited by 1,134
A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor
Schuurman, P. R., Bosch, D. A., Bossuyt, P. M. M., Bonsel, G. J., van Someren, E. J. W., de Bie, R. M. A., Merkus, M. P., & Speelman, J. D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420703 · Cited by 1,044
A summary of mechanistic hypotheses of gabapentin pharmacology
Taylor, C. P., Gee, N. S., Su, T.-Z., Kocsis, J. D., Welty, D. F., Brown, J. P., Dooley, D. J., Boden, P., & Singh, L. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(97)00084-3 · Cited by 774
High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
Koller, W., Pahwa, R., Busenbark, K., Hubble, J., Wilkinson, S., Lang, A., Tuite, P., Sime, E., Lazano, A., Hauser, R., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420304 · Cited by 478
Self-citationLouis, E. D., Ottman, R., & Allen Hauser, W. (1998) · Movement Disorders · doi:10.1002/mds.870130105 · Cited by 424
Essential tremor: Clinical correlates in 350 patients
Lou, J.-S., & Jankovic, J. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.234 · Cited by 375
Self-citation
Research works printed but not linked: 14
- Sevitt, 1971, Practitioner, 207, 677
- Winkler, 1971, Trans Am Neurol Assoc, 96, 66
- Murray, 1976, Can Med Assoc J, 115, 892
- Dupont, 1973, Acta Neurol Scand, 69, 75
- Huttunen, 1984, Lancet, II, 857
- Britt, 1979, N Engl J Med, 301, 331
- Ljung, 1979, N Engl J Med, 301, 1005
- Riley, 1979, N Engl J Med, 301, 663
- Connor, 1999, Mov Disord, 14, 908
- Jimenez-Jimenez, 1994, Acta Neurol (Napoli), 16, 184
- Ertan, 2000, Mov Disord, 15, 102
- Ohye, 1982, Appl Neurophysiol, 45, 275
- Benabid, 1993, Acta Neurochir Suppl (Wien), 58, 39
- Bilodeau, 2000, Muscle Nerve, 23, 771, 10.1002/(SICI)1097-4598(200005)23:5<771::AID-MUS15>3.0.CO;2-9 · doi:10.1002/(sici)1097-4598(200005)23:5<771::aid-mus15>3.0.co;2-9
Cited by
Pharmacotherapy of Essential Tremor: An Overview of Existing and Upcoming Agents
Lyons, K. E., & Pahwa, R. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00006 · Cited by 235
Self-citationAlterio, V., Vitale, R. M., Monti, S. M., Pedone, C., Scozzafava, A., Cecchi, A., De Simone, G., & Supuran, C. T. (2006) · Journal of the American Chemical Society · doi:10.1021/ja061574s · Cited by 203
Deep brain stimulation in the posterior subthalamic area in the treatment of essential tremor
Blomstedt, P., Sandvik, U., & Tisch, S. (2010) · Movement Disorders · doi:10.1002/mds.22758 · Cited by 203
“It is often associated with significant disability and 50% of the patient population proves to be refractory to pharmacological treatment.(3) In these cases, functional stereotactic neurosurgery might constitute an alternative.”
BackgroundDefective dentate nucleus GABA receptors in essential tremor
Paris-Robidas, S., Brochu, E., Sintes, M., Emond, V., Bousquet, M., Vandal, M., Pilote, M., Tremblay, C., Di Paolo, T., Rajput, A. H., et al. (2012) · Brain · doi:10.1093/brain/awr301 · Cited by 198
“The standard pharmaceutical care of essential tremor has essentially not changed in the last 40 years and still relies on primidone and propranolol, which display moderate efficacy to decrease the amplitude of tremor in less than half of patients (Lyons et al., 2003; Louis et al., 2010; Deuschl et al., 2011).”
BackgroundMenchise, V., De Simone, G., Alterio, V., Di Fiore, A., Pedone, C., Scozzafava, A., & Supuran, C. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050333c · Cited by 159
Metadata
- Authors
- Lyons, K. E., Pahwa, R., Comella, C. L., Eisa, M. S., Elble, R. J., Fahn, S., Jankovic, J., Juncos, J. L., Koller, W. C., Ondo, W. G., Sethi, K. D., Stern, M. B., Tanner, C. M., Tintner, R., & Watts, R. L.
- Affiliations
- University of Kansas Medical Center (US)
- Rush University Medical Center (US)
- Pennsylvania Hospital (US)
- SIU Medicine (US)
- Columbia University (US)
- Baylor College of Medicine (US)
- Emory University (US)
- Mount Sinai Hospital (US)
- Augusta University (US)
- Parkinson's Institute and Clinical Center (US)
- Corresponding author
- Pahwa, Rajesh
- ORCID
- Venue
- Drug Safety
- Published
- 2003
- Volume
- 26
- Issue
- 7
- Pages
- 461-481
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2121739059
- Cited by
- 103
- References
- 140
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 2 · 2012: 10
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- essential tremor, pharmacotherapy, primidone, propranolol, benzodiazepines, beta-blockers, gabapentin, topiramate, botulinum toxin, deep brain stimulation, thalamotomy, surgical treatment, functional disability, tremor control, adverse drug reactions, carbonic anhydrase inhibitors, clonidine, mirtazapine
- MeSH terms
- Adrenergic Agonists, Anticonvulsants, Clinical Trials as Topic, Electric Stimulation Therapy, Humans, Neuromuscular Agents, Primidone, Risk Assessment, Essential Tremor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits and Risks of Pharmacological Treatments for Essential Tremor. https://app.cochat.ai/papers/10.2165/00002018-200326070-00003
- The paper
- Lyons, K. E., Pahwa, R., Comella, C. L., Eisa, M. S., Elble, R. J., Fahn, S., Jankovic, J., Juncos, J. L., Koller, W. C., Ondo, W. G., Sethi, K. D., Stern, M. B., Tanner, C. M., Tintner, R., & Watts, R. L. (2003). Benefits and Risks of Pharmacological Treatments for Essential Tremor. Drug Safety. https://doi.org/10.2165/00002018-200326070-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.